Clinical trials · Texas
Glioma clinical trials in Texas
We’re tracking 32 recruiting glioma studies with a site in Texas — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT06333899RecruitingEarly Phase 1
Lorlatinib for newly diagnosed brain tumors with ROS or ALK fusion
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
Houston, TexasAges 1–21 - NCT05839379Recruiting
Targeted therapy study for children and young adults with brain tumors
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Houston, TexasAges 1–39 - NCT05843253RecruitingPhase 2
Ribociclib plus everolimus or temozolomide for certain brain tumors
This Phase 2 study tests ribociclib with either everolimus or temozolomide, depending on the specific brain tumor type. It may help slow tumor growth in children and young adults whose tumor has specific genetic changes and who have had recent standard radiation therapy.
Houston, TexasAges 1–39 - NCT04166409RecruitingPhase 3
Selumetinib versus chemo for low-grade brain tumor in children
This trial studies whether the targeted drug selumetinib works better than standard chemotherapy (carboplatin and vincristine) for children and young adults with a specific type of low-grade glioma (grade 1 or 2). It may help shrink tumors and slow growth while comparing side effects between the two treatment approaches.
Austin, TexasAges 2–21 - NCT06161974RecruitingPhase 2
Olutasidenib and temozolomide for IDH1-mutant high-grade glioma
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
Houston, TexasAges 12–39 - NCT04485559RecruitingPhase 1
Trametinib and everolimus for recurrent gliomas
This trial tests two drugs, trametinib and everolimus, for children and young adults with recurrent or progressive gliomas (a type of brain tumor). The goal is to see if this drug combination is safe and effective in treating these tumors.
Dallas, TexasAges 1–25 - NCT06838676RecruitingPhase 2
ACT001 for DIPG and H3K27-altered high-grade gliomas
This trial tests a drug called ACT001 for people with diffuse intrinsic pontine glioma (DIPG) or certain high-grade gliomas that have a specific genetic change (H3K27-altered). It includes two groups: one for newly diagnosed DIPG after radiation, and another for progressive or recurrent disease.
Houston, TexasAges 1–39 - NCT05099003RecruitingPhase 1/Phase 2
Selinexor plus radiation for newly diagnosed brain tumors
This trial studies whether adding selinexor to standard radiation can improve outcomes for children and young teens with certain newly diagnosed high-grade brain tumors (including DIPG). It’s designed for specific tumor types and genetic markers, and people must be able to start treatment soon after diagnosis.
Austin, TexasAges 1–21 - NCT04373720Recruiting
MRI scan to tell scar from tumor in treated brain glioma
This study uses an advanced MRI scan to help doctors tell the difference between radiation scar (radiation necrosis) and returning glioma (recurrent glioma) after prior treatment. It may help guide the next steps for care if you have a new or changing brain lesion.
Houston, TexasAges 18 years+ - NCT04623931RecruitingPhase 2
Chemo and radiation for IDH-wildtype glioma
This Phase 2 study tests a combination of chemotherapy and radiation after surgery for certain brain tumors that are “IDH wildtype.” It aims to control the tumor and improve outcomes for people with specific types of glioma or glioblastoma.
Houston, TexasAges 18 years+ - NCT04655404RecruitingEarly Phase 1
Larotrectinib for children with newly diagnosed glioma with NTRK fusion
This trial tests larotrectinib, a targeted cancer medicine, in children and teens with newly diagnosed high-grade brain glioma that has an NTRK fusion. It may help shrink or control tumors by targeting a specific genetic change in the cancer.
Houston, TexasAges Up to 21 years - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Fort Worth, TexasAges 1–21 - NCT05538130RecruitingPhase 1
Study medicine for BRAF-mutated advanced solid tumors
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
Houston, TexasAges 16 years+ - NCT05303519RecruitingPhase 3
Safusidenib for IDH1-mutant glioma after main treatment
This Phase 3 trial tests safusidenib, a targeted medicine, to help stop or slow the return of certain brain tumors with an IDH1 mutation. It focuses on people after initial treatment (surgery and/or radiation and temozolomide), aiming to improve outcomes during maintenance therapy.
Houston, TexasAges 18 years+ - NCT04775485RecruitingPhase 2
Targeted medicine for children with certain brain or solid tumors
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
Houston, TexasAges 6 months–25 years - NCT04479696Recruiting
Video coaching to ease anxiety during brain tumor radiation
This study tests a personalized video meant to reduce stress and anxiety for people getting radiation for brain tumors, and for their caregivers. You and your caregiver would complete short questionnaires before and after using the video support.
Houston, TexasAges 18 years+ - NCT03896568RecruitingPhase 1
Trial of stem cell therapy for recurrent high-grade brain tumors
This Phase 1 study tests an advanced stem-cell treatment (hMSC-DNX2401) for recurrent high-grade glioma, including certain brain tumor types that come back. It aims to see if the treatment can be safely delivered and whether it can help control the tumor after standard therapies have already been tried.
Houston, TexasAges 18 years+ - NCT04099797RecruitingPhase 1
CAR T therapy for certain GD2 brain tumors
This Phase 1 study tests CAR T cells designed to target a marker called GD2 on brain tumors. It aims to see if the treatment is safe and whether it can shrink or control these tumors in children and young adults.
Houston, TexasAges 1–25 - NCT04771806Recruiting
MRI-guided adaptive radiation for high-grade brain tumors
This study uses repeated MRI scans with a contrast dye to help doctors tailor (adapt) your radiation treatment over time for a high-grade glioma. It may help improve how accurately radiation targets the tumor as it changes.
Houston, TexasAges 18 years+ - NCT05096481RecruitingPhase 2
Vaccine trial for children with certain brain tumors
This Phase 2 study tests a vaccine made to target CMV (a virus) in order to treat children with medulloblastoma or newly diagnosed high-grade glioma/DIPG. If you’re eligible, you’d receive the study vaccine and the team would closely watch how well it’s tolerated and how your cancer responds.
Houston, TexasAges 3–39 - NCT05580562RecruitingPhase 3
ONC201 for newly diagnosed H3 K27M brain tumor after radiation
This study tests whether ONC201 (also called ONC201) can improve outcomes for people with a newly diagnosed H3 K27M–mutant diffuse brain tumor after they finish radiation. It looks for safety and whether treatment can help control the tumor.
Houston, TexasAges Any age - NCT05804227RecruitingEarly Phase 1
Ulixertinib for glioma driven by MAPK pathway
This early-phase trial tests ulixertinib (a targeted pill) to see how well it works for certain gliomas driven by the MAPK/RAF-MEK-ERK signaling pathway. It also looks at whether the drug can help control tumor growth around the time of treatment planning.
Houston, TexasAges 18 years+ - NCT06810544RecruitingPhase 1/Phase 2
Study of TNG456 for tumors with MTAP loss
This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.
Houston, TexasAges 18 years+ - NCT07076498RecruitingPhase 1
Gene therapy for children and adults with diffuse midline glioma
This trial tests a modified herpes virus (M032) given directly into the brain tumor after standard radiation. The goal is to see if this virus can slow or stop the growth of diffuse midline glioma, a type of brain cancer.
Houston, TexasAges 3 years+
Glioma trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting glioma studies listed above.
- The University of Texas MD Anderson Cancer Center · 13 studies
- Texas Children's Hospital · 9 studies
- University of Texas Southwestern Medical Center · 6 studies
- Baylor College of Medicine · 3 studies
- Cook Children's Medical Center · 3 studies
- Dell Children's Medical Center · 3 studies
- University of Texas Health Science Center at San Antonio · 3 studies
- Children's Hospital of San Antonio · 2 studies
What taking part in a glioma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Glioma trials in other states
Common questions
- Are there glioma clinical trials in Texas?
- Yes. We're currently tracking 32 recruiting glioma studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a glioma study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a glioma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New glioma studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.